Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Inhaled Levodopa (CVT-301) in Parkinson's Disease
NCT02352363Phase 3Completed
- Sponsor
- Acorda Therapeutics
- Start
- Mar 2015
- Primary completion
- May 2017
- Modality
- Small Molecules
- Countries
- 14
01
Overview
A Phase 3 trial of levodopa in Parkinson's disease (PD), sponsored by Acorda Therapeutics. Started Mar 2015; status: completed.
02
Drugs
levodopa
03
Conditions
Parkinson's disease (PD)
Beyond the preview
Go deeper on NCT02352363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02352363.